davidalexandre gros  alnylam pharmaceuticals  inc  zoominfocom compensation information for davidalexandre c gros md former senior vice president chief business officer former principal financial officer of alnylam pharmaceuticals inc  salarycom enterprise small business personal contact us log in salaries jobs education advice davidalexandre c gros md executive compensation as former senior vice president chief business officer former principal financial officer at alnylam pharmaceuticals inc davidalexandre c gros md made  in total compensation of this total  was received as a salary  was received as a bonus  was received in stock options  was awarded as stock and  came from other types of compensation this information is according to proxy statements filed for the  fiscal year enter an executive or company name new search go the chart on this page features a breakdown of the total annual pay for davidalexandre c gros md former senior vice president chief business officer former principal financial officer at alnylam pharmaceuticals inc as reported in their proxy statements total cash compensation information is comprised of yearly base pay and bonuses alnylam pharmaceuticals inc income statements for executive base pay and bonus are filed yearly with the sec in the edgar filing system alnylam pharmaceuticals inc annual reports of executive compensation and pay are most commonly found in the def a documents total equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year other compensation covers all compensationlike awards that dont fit in any of these other standard categories numbers reported do not include change in pension value and nonqualified deferred compensation earnings other executives at this company john m maraganore phd barry e greene akshay k vaishnaw mdphd michael p mason yvonne l greenstreet mbchb davidalexandre c gros md base pay bonus  incentive comp total cash compensation stock award value option award value total equity total other total compensation browse executives by first name a b c d e f g h i j k l m n o p q r s t u v w x y z browse companies by company name a b c d e f g h i j k l m n o p q r s t u v w x y z  this report is not for commercial use thorough reviews have been conducted to assure this data accurately reflects disclosures however for a complete and definitive understanding of the pay practices of any company users should refer directly to the actual complete proxy statement use of data  disclaimer the information shown here is a reporting of information included in the companys proxy statement the proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information for those interested in conducting a detailed compensation analysis we recommend that you review the entire proxy statement you may retrieve the full proxy statement by going to the securities and exchange commission sec website at wwwsecgov and entering the companys name and then looking in the first column for an entry of form def a or any similar code you may also find the annual proxy statement by going directly to the companys website what is a proxy statement a proxy statement or proxy is a form that every publicly traded us company is required to file with the us securities  exchange commission sec within  days after the end of its fiscal year the proxy must be sent to every shareholder in advance of the companys annual shareholders meeting all proxy statements are public filings made available to the general public by the sec the proxy statements main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting including decisions such as electing directors ratifying the selection of auditors and other shareholderrelated decisions including shareholderinitiated initiatives also proxies must disclose specific detailed information regarding the pay practices for certain executives       privacy policy terms of use about us contact us  salarycom all rights reserved us salaries canadian salaries purchase a salary report salaries by category salaries by income salaries by industry popular salaries negotiation tips benefits calculator search job openings job openings by state job openings by category education by career education by level education by major cost of living calculator david alexandre gros  san francisco ca  intelius sign in we found david alexandre gros in san francisco ca david alexandre gros intelius found that david alexandre gros is a male between  and  years old from san francisco ca we have connected them to  addresses  phones and  relative or associate also known as davidalexandre c gros david c gros d a gros davidalexandre da gros davidalexan a gros get report now age david alexandre gros is in his s david has lived in san francisco ca boston ma chicago il davids relatives marlyse gros david alexandre gros zodiac signcancer gendermale professional status senior vice president chief business officer at alnylam pharmaceuticals  inc get report now want to know more about david get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about david or use our people search engine to find others get background check on david alexandre gros get a criminal check on david alexandre gros get a public record report on david alexandre gros get a people search report on david alexandre gros david alexandre gross contact information known cities lived in find out where david alexandre gros has lived as well as david alexandre gross phone numbers and email addresses david alexandre gros has lived in  states california address for david alexandre gros  g s san francisco ca has lived in san francisco ca boston ma get full address report phone numbers associated with david alexandre gros    cambridge ma 9   bridgewater nj    new york ny get full phone report email addresses associated with david alexandre gros decom dscom dscom get email report david alexandre gross education information known schools attended learn about david alexandre gross academic history find out which schools david alexandre gros attended the dates attended as well as the degrees david alexandre gros received the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act david alexandre gros has attended  schools harvard business school  –  harvard business school  –  david alexandre gros has a mba mba in mba the johns hopkins university school of medicine 99 – 999 the johns hopkins university school of medicine 99 – 999 david alexandre gros has a md md in md dartmouth college 99 – 99 dartmouth college 99 – 99 david alexandre gros has a ab ab in ab david alexandre gross professional information information regarding david alexandre gross professional history find out previous places david alexandre gros has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act david alexandre gros has worked at  places company alnylam pharmaceuticals  inc title senior vice president chief business officer company mckinsey  company title consultant in healthcare practice david alexandre gross experience title senior vice president chief business officer company alnylam pharmaceuticals  inc job details company size  mil to less than  mil  employee range  to less than  title consultant in healthcare practice company mckinsey  company job details company size less than  mil  employee range  to less than  mckinsey  company is a global management consulting firm dedicated to helping the worlds leading organizations address their strategic challenges with consultants deployed in more than  countries around the globe mckinsey advises on strategic operational organizational and technological issues for more than eight decades the firms primary objective has been to serve as an organizations most trusted external advisor on critical issues facing senior management additional professional information on david alexandre gros see david alexandre gross linkedin profile david alexandre gross social network and potential email matches find out potential social network profiles and potential email usernamed for david alexandre gros david alexandre gross known social networks and potential email matches find all of david alexandre gross social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches david gros username matches davidgros grosdavid davidgros grosdavid davidgros grosdavid davidgros grosdavid dgros popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches d gros intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here alnylam appoints davidalexandre gros md senior vice president chief business officer  business wire alnylam appoints davidalexandre gros md senior vice president chief business officer june    am eastern daylight time cambridge massbusiness wirealnylam pharmaceuticals inc nasdaqalny a leading rnai therapeutics company today announced the appointment of davidalexandre “da” gros md to the position of senior vice president chief business officer dr gros joins alnylam with extensive experience in the pharmaceutical industry and in healthcare investment banking and consulting at alnylam he will be responsible for the company’s corporate and business development finance corporate communications and investor relations functions in addition dr gros will be joining the alnylam management board “we are in a very exciting period of growth at alnylam as we aim to execute on our ‘alnylam ’ goals and transition from a latestage clinical development company to become a multiproduct commercial stage company with a sustainable development pipeline” said john maraganore phd chief executive officer of alnylam “da brings to alnylam an impressive array of experiences in the pharmaceutical industry and in healthcare investment banking and management consulting in addition his background in corporate strategy will prove invaluable as we execute on our alnylam  goals we’re thrilled to have him join our team” “alnylam is a remarkably innovative company leading the advancement of rnai therapeutics as a new class of innovative medicines to address major unmet needs for a wide range of diseases globally with a history of building significant alliances” said dr gros “i’m particularly excited to join the team during this pivotal period in capitalizing on the company’s potential and contributing to its continued success” most recently dr gros was executive vice president and chief strategy officer at sanofi where he was a member of the executive committee and the global leadership team his responsibilities included leading corporate strategy business development and licensing mergers and acquisitions alliance management and structured investments including the corporate venture fund during his tenure he oversaw the execution of over  successful transactions and the launch of sanofi’s corporate venture activities and he was closely involved in the company’s key alliances with alnylam and regeneron prior to sanofi he held management positions with a focus on the pharmaceutical industry in investment banking at centerview partners and merrill lynch  co and in consulting at mckinsey  co dr gros holds an md from the johns hopkins university school of medicine an mba from harvard business school and a ba from dartmouth college about rnai rnai rna interference is a revolution in biology representing a breakthrough in understanding how genes are turned on and off in cells and a completely new approach to drug discovery and development its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so” and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the  nobel prize for physiology or medicine rnai is a natural process of gene silencing that occurs in organisms ranging from plants to mammals by harnessing the natural biological process of rnai occurring in our cells the creation of a major new class of medicines known as rnai therapeutics is on the horizon small interfering rna sirna the molecules that mediate rnai and comprise alnylams rnai therapeutic platform target the cause of diseases by potently silencing specific mrnas thereby preventing diseasecausing proteins from being made rnai therapeutics have the potential to treat disease and help patients in a fundamentally new way about alnylam pharmaceuticals alnylam is a biopharmaceutical company developing novel therapeutics based on rna interference or rnai the company is leading the translation of rnai as a new class of innovative medicines alnylam’s pipeline of investigational rnai therapeutics is focused in  strategic therapeutic areas stars genetic medicines with a broad pipeline of rnai therapeutics for the treatment of rare diseases cardiometabolic disease with a pipeline of rnai therapeutics toward genetically validated liverexpressed disease targets for unmet needs in cardiovascular and metabolic diseases and hepatic infectious disease with a pipeline of rnai therapeutics that address the major global health challenges of hepatic infectious diseases in early  alnylam launched its “alnylam ” guidance for the advancement and commercialization of rnai therapeutics as a whole new class of innovative medicines specifically by the end of  alnylam expects to achieve a company profile with  marketed products  rnai therapeutic clinical programs – including  in late stages of development – across its  stars the company’s demonstrated commitment to rnai therapeutics has enabled it to form major alliances with leading companies including merck medtronic novartis biogen roche takeda kyowa hakko kirin cubist glaxosmithkline ascletis monsanto the medicines company and genzyme a sanofi company in addition alnylam holds an equity position in regulus therapeutics inc a company focused on discovery development and commercialization of microrna therapeutics alnylam scientists and collaborators have published their research on rnai therapeutics in over  peerreviewed papers including many in the world’s top scientific journals such as nature nature medicine nature biotechnology cell new england journal of medicine and the lancet founded in  alnylam maintains headquarters in cambridge massachusetts for more information about alnylam’s pipeline of investigational rnai therapeutics please visit wwwalnylamcom alnylam forward looking statements various statements in this release concerning alnylam’s future expectations plans and prospects including without limitation alnylam’s expectations regarding its “alnylam ” guidance alnylam’s views with respect to the potential for rnai therapeutics and its plans regarding commercialization of rnai therapeutics constitute forwardlooking statements for the purposes of the safe harbor provisions under the private securities litigation reform act of 99 actual results may differ materially from those indicated by these forwardlooking statements as a result of various important factors including without limitation alnylam’s ability to manage operating expenses alnylam’s ability to discover and develop novel drug candidates and delivery approaches successfully demonstrate the efficacy and safety of its drug candidates the preclinical and clinical results for its product candidates which may not be replicated or continue to occur in other subjects or in additional studies or otherwise support further development of product candidates actions of regulatory agencies which may affect the initiation timing and progress of clinical trials obtaining maintaining and protecting intellectual property alnylam’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties obtaining regulatory approval for products competition from others using technology similar to alnylam’s and others developing products for similar uses alnylam’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives alnylam’s dependence on third parties for development manufacture marketing sales and distribution of products the outcome of litigation and unexpected expenditures as well as those risks more fully discussed in the “risk factors” filed with alnylam’s most recent quarterly report on form q filed with the securities and exchange commission sec and in other filings that alnylam makes with the sec in addition any forwardlooking statements represent alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date alnylam explicitly disclaims any obligation to update any forwardlooking statements contacts alnylam pharmaceuticals incmichael mason vice president finance and treasurerorspectrumliz bryan 9 ext  media contacts alnylam pharmaceuticals incmichael mason vice president finance and treasurerorspectrumliz bryan 9 ext  media search advanced news search advanced news search log in sign up neurocrine biosciences announces the appointment of davidalexandre gros md president and chief neurocrine biosciences announces the appointment of davidalexandre gros md president and chief operating officer news provided by neurocrine biosciences inc jan    et share this article san diego jan   prnewswire  neurocrine biosciences inc nasdaq nbix a biotechnology company focused on neurological and endocrine related disorders announced that davidalexandre da gros md has joined the executive management team as president and chief operating officer   neurocrine is very pleased to welcome dr gros as our president and chief operating officer as we move forward with our transformation into a commercial entity said kevin gorman chief executive officer of neurocrine biosciences das breadth of experience across all aspects of drug development and commercialization will be of critical importance as we enter this period of rapid growth he will also be instrumental in executing on our longrange strategic plans we are excited to have him join our team neurocrine is a remarkably innovative company leading the development of novel therapeutics to address major unmet needs in neurological and endocrine disorders said dr gros i am very excited to join the company during this pivotal growth phase and look forward to contributing to neurocrines continued success dr gros has extensive experience in developing and executing biopharmaceutical growth strategies he joins neurocrine from alnylam pharmaceuticals where he served as senior vice president chief business officer and was a member of the management board his responsibilities included strategy finance business development communications investor relations and shared services prior to alnylam as executive vice president and chief strategy officer at sanofi where he was a member of the executive committee dr gros responsibilities included corporate strategy business development and licensing mergers and acquisitions alliance management and structured investments including the corporate venture fund which he relaunched before sanofi dr gros held management positions of increasing responsibility with a focus on biotechnology and pharmaceuticals in investment banking at centerview partners and merrill lynch and in consulting at mckinsey  company dr gros holds an md from the johns hopkins university school of medicine an mba from harvard business school and a ba from dartmouth college neurocrine also announced the grant of an inducement award to dr gros pursuant to rule c of the nasdaq listing rules in connection with his employment by neurocrine dr gros will be granted an inducement award consisting of a stock option to purchase  shares of neurocrine common stock the stock option will vest over a period of four years with  vesting on the first anniversary of its grant date and the balance vesting each month over the remaining three years this award is subject to the terms and conditions of neurocrines inducement plan the award will be effective on february   which is the first day of the first calendar month following the commencement of dr gros employment with neurocrine and will have an exercise price equal to the closing price of neurocrines common stock on the nasdaq global select market on that date the award was granted as an inducement material to dr gros employment pursuant to rule c of the nasdaq listing rules about neurocrine biosciencesneurocrine biosciences inc discovers and develops innovative and lifechanging pharmaceuticals in diseases with high unmet medical needs through its novel rd platform focused on neurological and endocrine based diseases and disorders the companys two programs are elagolix a gonadotropinreleasing hormone antagonist in phase iii development for womens health that is partnered with abbvie inc and ingrezzatm a vesicular monoamine transporter  inhibitor for which an nda has been filed with the fda for the treatment of tardive dyskinesia and is in phase ii development for patients with tourette syndrome neurocrine plans to commercialize ingrezza in the united states upon approval of the nda by the fda  neurocrine biosciences inc news releases are available through the companys website via the internet at httpwwwneurocrinecom in addition to historical facts this press release may contain forwardlooking statements that involve a number of risks and uncertainties among the factors that could cause actual results to differ materially from those indicated in the forwardlooking statements are risks and uncertainties associated with neurocrines business and finances in general ingrezza development and commercialization the companys r  d pipeline and the company overall specifically the risks and uncertainties the company faces include risks that ingrezza or the companys other product candidates may not obtain regulatory approval or that the us food and drug administration or regulatory authorities outside the us may make adverse decisions regarding ingrezza or the companys other product candidates risks that clinical development activities may not be completed on time or at all risks that clinical development activities may be delayed for regulatory or other reasons may not be successful or replicate previous clinical trial results may fail to demonstrate that our product candidates are safe and effective or may not be predictive of realworld results or of results in subsequent clinical trials risks that the companys product candidates may be precluded from commercialization by the proprietary rights of third parties or have unintended side effects adverse reactions or incidents of misuse risks associated with the companys dependence on third parties for development manufacturing and marketing activities risks that the companys research programs will not identify preclinical candidates for further development  risks that the company will be unable to raise additional funding required to complete development of all of its product candidates risks and uncertainties relating to competitive products and technological changes that may limit demand for the companys products and other risks described in the companys quarterly report on form q for the quarter ended september   neurocrine disclaims any obligation to update the statements contained in this press release after the date hereof   to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesneurocrinebiosciencesannouncestheappointmentofdavidalexandregrosmdpresidentandchiefoperatingofficerhtml source neurocrine biosciences inc related links httpwwwneurocrinecom jan    et preview neurocrine announces completion of phase ii clinical study of vmat inhibitor ingrezza™ valbenazine in adults with tourette syndrome jan    et preview neurocrine provides update on fda advisory committee for ingrezza™ valbenazine for the treatment of tardive dyskinesia my news release contains wide tables view fullscreen also from this source  et neurocrine biosciences announces conference call and webcast to jul   9 et neurocrine biosciences announces the appointment of julie cooke explore more news releases in similar topics health care  hospitals medical pharmaceuticals pharmaceuticals personnel announcements you just read neurocrine biosciences announces the appointment of davidalexandre gros md president and chief operating officer news provided by neurocrine biosciences inc jan    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search alnylam pharmaceuticals inc  alnylam appoints davidalexandre gros md senior vice president chief business officer alnylam about alnylam about rnai delivery of rnai therapeutics scientific leadership strategic alliances intellectual property alnylam × ttr amyloidosis fap ttr amyloidosis fac hemophilia complementmediated disease porphyria cardiometabolic disease alpha antitrypsin deficiency hepatitis b virus infection betathalassemia and iron overload disorders other pipeline programs our story our culture careers management board of directors scientific advisory board               share this on delicious digg facebook linkedin twitter what is this alnylam appoints davidalexandre gros md senior vice president chief business officer  cambridge massbusiness wire alnylam pharmaceuticals inc nasdaqalny a leading rnai therapeutics company today announced the appointment of davidalexandre da gros md to the position of senior vice president chief business officer dr gros joins alnylam with extensive experience in the pharmaceutical industry and in healthcare investment banking and consulting at alnylam he will be responsible for the companys corporate and business development finance corporate communications and investor relations functions in addition dr gros will be joining the alnylam management board we are in a very exciting period of growth at alnylam as we aim to execute on our ‘alnylam  goals and transition from a latestage clinical development company to become a multiproduct commercial stage company with a sustainable development pipeline said john maraganore phd chief executive officer of alnylam da brings to alnylam an impressive array of experiences in the pharmaceutical industry and in healthcare investment banking and management consulting in addition his background in corporate strategy will prove invaluable as we execute on our alnylam  goals were thrilled to have him join our team alnylam is a remarkably innovative company leading the advancement of rnai therapeutics as a new class of innovative medicines to address major unmet needs for a wide range of diseases globally with a history of building significant alliances said dr gros im particularly excited to join the team during this pivotal period in capitalizing on the companys potential and contributing to its continued success most recently dr gros was executive vice president and chief strategy officer at sanofi where he was a member of the executive committee and the global leadership team his responsibilities included leading corporate strategy business development and licensing mergers and acquisitions alliance management and structured investments including the corporate venture fund during his tenure he oversaw the execution of over  successful transactions and the launch of sanofis corporate venture activities and he was closely involved in the companys key alliances with alnylam and regeneron prior to sanofi he held management positions with a focus on the pharmaceutical industry in investment banking at centerview partners and merrill lynch  co and in consulting at mckinsey  co dr gros holds an md from the johns hopkins university school of medicine an mba from harvard business school and a ba from dartmouth college about rnai rnai rna interference is a revolution in biology representing a breakthrough in understanding how genes are turned on and off in cells and a completely new approach to drug discovery and development its discovery has been heralded as a major scientific breakthrough that happens once every decade or so and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the  nobel prize for physiology or medicine rnai is a natural process of gene silencing that occurs in organisms ranging from plants to mammals by harnessing the natural biological process of rnai occurring in our cells the creation of a major new class of medicines known as rnai therapeutics is on the horizon small interfering rna sirna the molecules that mediate rnai and comprise alnylams rnai therapeutic platform target the cause of diseases by potently silencing specific mrnas thereby preventing diseasecausing proteins from being made rnai therapeutics have the potential to treat disease and help patients in a fundamentally new way about alnylam pharmaceuticals alnylam is a biopharmaceutical company developing novel therapeutics based on rna interference or rnai the company is leading the translation of rnai as a new class of innovative medicines alnylams pipeline of investigational rnai therapeutics is focused in  strategic therapeutic areas stars genetic medicines with a broad pipeline of rnai therapeutics for the treatment of rare diseases cardiometabolic disease with a pipeline of rnai therapeutics toward genetically validated liverexpressed disease targets for unmet needs in cardiovascular and metabolic diseases and hepatic infectious disease with a pipeline of rnai therapeutics that address the major global health challenges of hepatic infectious diseases in early  alnylam launched its alnylam  guidance for the advancement and commercialization of rnai therapeutics as a whole new class of innovative medicines specifically by the end of  alnylam expects to achieve a company profile with  marketed products  rnai therapeutic clinical programs  including  in late stages of development  across its  stars the companys demonstrated commitment to rnai therapeutics has enabled it to form major alliances with leading companies including merck medtronic novartis biogen roche takeda kyowa hakko kirin cubist glaxosmithkline ascletis monsanto the medicines company and genzyme a sanofi company in addition alnylam holds an equity position in regulus therapeutics inc a company focused on discovery development and commercialization of microrna therapeutics alnylam scientists and collaborators have published their research on rnai therapeutics in over  peerreviewed papers including many in the worlds top scientific journals such as nature nature medicine nature biotechnology cell new england journal of medicine and the lancet founded in  alnylam maintains headquarters in cambridge massachusetts for more information about alnylams pipeline of investigational rnai therapeutics please visit wwwalnylamcom alnylam forward looking statements various statements in this release concerning alnylams future expectations plans and prospects including without limitation alnylams expectations regarding its alnylam  guidance alnylams views with respect to the potential for rnai therapeutics and its plans regarding commercialization of rnai therapeutics constitute forwardlooking statements for the purposes of the safe harbor provisions under the private securities litigation reform act of 99 actual results may differ materially from those indicated by these forwardlooking statements as a result of various important factors including without limitation alnylams ability to manage operating expenses alnylams ability to discover and develop novel drug candidates and delivery approaches successfully demonstrate the efficacy and safety of its drug candidates the preclinical and clinical results for its product candidates which may not be replicated or continue to occur in other subjects or in additional studies or otherwise support further development of product candidates actions of regulatory agencies which may affect the initiation timing and progress of clinical trials obtaining maintaining and protecting intellectual property alnylams ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties obtaining regulatory approval for products competition from others using technology similar to alnylams and others developing products for similar uses alnylams ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives alnylams dependence on third parties for development manufacture marketing sales and distribution of products the outcome of litigation and unexpected expenditures as well as those risks more fully discussed in the risk factors filed with alnylams most recent quarterly report on form q filed with the securities and exchange commission sec and in other filings that alnylam makes with the sec in addition any forwardlooking statements represent alnylams views only as of today and should not be relied upon as representing its views as of any subsequent date alnylam explicitly disclaims any obligation to update any forwardlooking statements view source version on businesswirecom httpwwwbusinesswirecomnewshome9en alnylam pharmaceuticals incmichael mason vice president finance and treasurerorspectrumliz bryan 9 ext  media source alnylam pharmaceuticals news provided by acquire media search search recent press releases  alnylam to host fourth annual rnai roundtable webcast series  alnylam and sanofi genzyme report positive results from ongoing phase  openlabel extension study with investigational rnai therapeutic fitusiran in patients with hemophilia a and b with or without inhibitors  alnylam and sanofi genzyme initiate atlas phase  program with investigational rnai therapeutic fitusiran in patients with hemophilia a and b with or without inhibitors view all releases nasdaq alny common price  change  9  volume  data as of  pm et on minimum  minute delay learn more microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext9 personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft davidalexandre c gros  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors davidalexandre c gros check out list of companies and businesses related to davidalexandre c gros find out davidalexandre c gros address and contact details view other people related to davidalexandre c gros  coworkers colleagues companions etc address  third street cambridge  ma companies related to davidalexandre c gros cikcompany namepositioncompany address9neurocrine biosciences incpresident  coo  el camino real san diego 9alnylam pharmaceuticals incsvp chief business officer  third street cambridge  davidalexandre c gros on the web persons related to davidalexandre c gros  neurocrine biosciences incnamepositioncityadrian adamsdirector westoneric benevichchief commercial officer san diegobiotechnology value fund ii lpchicagobiotechnology value fund ii lpchicagobiotechnology value fund ii lpchicagobiotechnology value fund l pchicagobiotechnology value fund l pchicagohaig p bozigianchief development officer san diegohaig p bozigianchief development officer san diegohaig p bozigianchief development officer san diegobvf incilchicagobvf incilchicagobvf incilsan franciscobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner san franciscobvf partners l pil owner chicagobvf partners l pilchicagobvf partners l pilchicagotimothy p coughlinchief financial officer san diegotimothy p coughlinchief financial officer san diegotimothy p coughlinchief financial officer san diegokyle ganochief business development off san diegokyle ganochief business dev officer san diegokevin charles gormanchief executive officer san diegokevin charles gormansr vp business development san diegokevin charles gormanpresident and ceo san diegokevin charles gormanpresident and ceo san diegokevin charles gormanpresident  ceo san diegokevin charles gormanpresident and ceo san diegodimitri e grigoriadischief research officer san diegodimitri e grigoriadischief research officer san diegodimitri e grigoriadischief research officer san diegodavidalexandre c grospresident  coo cambridgepaul w hawranexecutive vp and cfo san diegopaul w hawranexecutive vp and cfo san diegopaul w hawranexecutive vp and cfo san diegoanders d hovenew yorkanders d hovenew yorkmark n lampertchicagomark n lampertchicagodarin lippoldtchief legal officer san diegodarin lippoldtchief legal officer san diegorobert j littlesvp commercial operations san diegomalcolm lloydsmithchief regulatory officer san diegomalcolm lloydsmithchief regulatory officer san diegomalcolm lloydsmithchief regulatory officer san diegocorinne h lyledirector irvinecorinne h lyledirector irvinegary a lyonsdirector palo altogary a lyonspresident and ceo san diegogary a lyonspresident and ceo san diegow thomas mitchelldirector la quintaw thomas mitchelldirector san diegojoseph a mollicadirector joseph a mollicadirector cranburyjoseph a mollicadirector princetonjoseph a mollicadirector cranburyjoseph a mollicadirector cranburygeorge j morrowdirector neurocrine biosciences incdirector san diegocorinne h nevinnydirector irvinecorinne h nevinnydirector san diegochristopher flint obrienchief medical officer san diegochristopher flint obriensr vp  chief medical officer san diegochristopher flint obrienchief medical officer san diegochristopher flint obrienchief medical officer san diegohenry panexecutive vp and cmo san diegohenry panexecutive vp and cmo san diegorichard f popsdirector cambridgerichard f popsdirector walthamrichard f popsdirector cambridgerichard j ranierisr vp human resources san diegorichard j ranierisr vp human resources san diegowilliam h rastetterdirector william h rastetterdirector san diegobryan e robertspalo altoalfred sandrockdirector westonstephen a sherwindirector south san franciscostephen a sherwindirector san diegostephen a sherwindirector south san franciscolawrence steinmandirector stanfordlawrence j steinmancynthia j thomassan diegowylie w valedirector la jollajensen margaret e valeursenior vp and general counsel san diegojensen margaret e valeursenior vp and general counsel san diegojensen margaret e valeurevp and general counsel san diegojensen margaret e valeurevp and general counsel san diegovenrock healthcare capital partners lppalo altovhcp coinvestment holdings llcpalo altovhcp management llcpalo altowendall wierengaevp research  development san diegowendall wierengaevp research  development san diegowendall d wierengasan diegowendall d wierengaevp research  development san diegopersons related to davidalexandre c gros  alnylam pharmaceuticals incnamepositioncityabingworth management ltdlondonabingworth management ltd owner londonabingworth management ltd owner londonpatricia l allenvp finance and treasurer cambridgepatricia l allenvp of finance and treasurer cambridgepatricia l allenvp of financetreasurer andoverarch v entrepreneurs fund lpchicagoarch venture fund v lpchicagoarch venture partners v llcchicagoarch venture partners v lpchicagostephen d arnoldwalthamstephen d arnoldwalthamatlas venture associates v lpwalthamatlas venture associates v lpwalthamatlas venture associates vi lpwalthamatlas venture associates vi lpwalthamatlas venture entrepreneurs fund v lpwalthamatlas venture entrepreneurs fund v lpwalthamatlas venture entrepreneurs fund vi lpwalthamatlas venture entrepreneurs fund vi lpwalthamatlas venture fund v lp owner walthamatlas venture fund v lp owner walthamatlas venture fund vi gmbh  co kgwalthamatlas venture fund vi gmbh  co kgwalthamatlas venture fund vi lpwalthamatlas venture fund vi lpwalthamatlas venture parallel fund va c vwalthamatlas venture parallel fund va c vwalthamatlas venture parallel fund vb c vwalthamatlas venture parallel fund vb c vwalthamdennis a ausiellodirector new yorkdennis a ausiellodirector cambridgedennis a ausiellodirector cambridgepeter barrettcambridgepeter barrettdirector walthampeter barrettdirector walthampeter barrettdirector walthamjohn e berrimanlondonjohn e berrimandirector londonjohn e berrimandirector cambridgemichael w bonneydirector lexingtonmichael w bonneycambridgeclinton bybeechicagochp ii lp owner princetonjohn k clarkedirector princetonjohn k clarkedirector princetonjohn k clarkecambridgejohn k clarkedirector princetonjohn k clarkedirector princetonjohn k clarkedirector cambridgekeith crandellchicagovictor j dzaudirector cambridgevictor j dzaucambridgevictor j dzaudirector cambridgemarsha fanuccidirector cambridgemarsha fanuccidirector cambridgemarsha fanuccidirector cambridgemarsha fanuccidirector cambridgejonathan a flintwalthamjonathan a flintwalthambarry e greenepresident cambridgebarry e greenepresident and coo cambridgebarry e greenepresident and coo cambridgeyvonne greenstreetevp chief commercial officer cambridgedavidalexandre c grossvp chief business officer cambridgelaurie keatingsvp gc  secretary cambridgekenneth s koblanchief scientific officer cambridgesteven lazaruschicagojohn maraganorechief executive officer cambridgejohn maraganorecambridgejohn maraganorepresident  ceo cambrdigejohn maraganoreceo cambridgejohn maraganoreceo cambridgejohn maraganoreceo cambridgejohn maraganoreceo cambridgemichael masonvp finance and treasurer cambridgemichael masonvp finance and tresurer cambridgemichael masonvp finance and treasurer cambridgeterrance mcguirewalthamterrance mcguirewalthamvincent j milessenior vp business development cambridgerobert nelsenchicagoag novartis owner basel switzerlandag novartis owner basel switzerlandag novartis owner baselpharma ag novartisbasel switzerlandpharma ag novartisbasel switzerlandpharma ag novartisbaselsteven m pauldirector steven m pauldirector cambridgesteven m paulcambridgesteven m pauldirector cambridgepolaris venture management co iii llc owner walthampolaris venture partners entrepreneurs fund iii lpwalthampolaris venture partners entrepreneurs fund iii lpwalthampolaris venture partners founders fund iii lpwalthampolaris venture partners founders fund iii lpwalthampolaris venture partners iii lpwalthampolaris venture partners iii lpwalthamdavid e i pyottdirector laurence reidsvp chief business officer cambridgelaurence reidsvp chief business officer cambridgesanofi owner parissanofiaventis owner parisvicki l satodirector cambridgevicki l satodirector cambridgepaul schimmeldirector cambridgepaul schimmeldirector cambridgepaul schimmeldirector cambridgepaul schimmeldirector cambridgejohn a schmidt jrsvp chief scientific officer cambridgeamy w schulmandirector new yorkamy w schulmancambridgeedward m scolnickdirector cambridgephilip a sharpdirector cambridgephilip a sharpdirector cambridgephilip a sharpdirector cambridgephilip a sharpdirector cambridgephilip a sharpdirector cambridgemanmeet singh sonisunnyvalealan g spoonwalthamalan g spoonwalthamkevin p starrdirector cambridgekevin p starrdirector cambrdigekevin p starrdirector cambridgekevin p starrdirector cambridgethomas r ulichcambridgeakshay vaishnawevp rd cambridgeakshay vaishnawevp chief medical officer cambridgeakshay vaishnawevp chief medical officer cambridgeakshay vaishnawevp chief medical officer cambridgejames l vincentdirector cambridgejames l vincentdirector cambridgechristoph h westphalcambridgechristoph h westphaldirector walthamchristoph h westphaldirector waltham davidalexandre c gros  san francisco ca  company information products resources my account talk to a db advisor  business directory ca san francisco nonclassifiable establishments nonclassifiable establishments davidalexandre c gros d davidalexandre c gros claim this business  jones st unit  san francisco ca 99 get directions business info founded  incorporated annual revenue  employee count  industries nonclassifiable establishments contacts contact business your email address subject message send message company summary since  davidalexandre c gros has been providing nonclassifiable establishments from san francisco verified status unverified address unverified last verified  phone unverified payment method unverified view full report similar businesses nearby our similar businesses nearby shows similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile competitive landscape our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile payments accepted no data hours sunday   monday   tuesday   wednesday   thursday   friday   saturday   d view additional data select from over  networks below to view available data about this business if this data is unavailable or inaccurate and you own or represent this business click here for more information on how you may be able to correct it credibility review google facebookcom yellowbookcom bingcom yellowpagescom merchantcircle tele atlas tomtom twittercom aol mapquest yahoo local applesiri groupon hotfrogcom comcastnet search reachlocal admedia dealsplus shoptopiacom alteryx dogtime media kslcom sirtune americantownscom driverside kudzucom specialsagentcom answerscom egood lawinfocom spotlikescom anywhocom egumball likenesscom spotzot eservicelog mapmyrun technocom apartmentguidecom ezlocalcom eztousecom teleroute aroundmecom metropolistcom therapistscom atlanta newhomes findlawcom time out new york avantar findthebestcom mojopagescom bb yellowpages fivestar software mycitywaycom tripadvisor bckyrdcom giftcardscom mycouponscom beachcaliforniacom golocalcom mymovecom upmesocialcom belo goodinfo newsgazette nokia usdirectorycom carscom nomao centzycom hibu openlistcom chacha search homeplatecom ownlocalcom visikard challamacom homestore patchcom voltari citybot pelopidas vouchd classifiedads hostway placeiq walkscorecom cloudmade hoodoyou planetdiscovercom weddingwirecom powerprofiles where inc contractorscom igolocalcom radiate media wikiocity couponmap indeedcom wimgocom crowdspot innova electronics intellistrand realtorcom datasphere inthemocom replycom yellowbotcom jiwire rocket fuel yellowpagecitycom dmvorg justclicklocalcom dirxion keencom zidstercom photos business credit report receive a onetime comprehensive credit report on this company get full credit report facebook twitter yelp call  to speak with a db advisor today customer resources products education center business articles  insights glossary contact us customer support communication preferences search for db duns our company about us company history business credit history careers press releases news success stories hoovers our network partners affiliates blog access to capital entrepreneurial initiative db international supplieredge site links business directory site map pipeda privacy policy website terms of service product license agreement  dun  bradstreet inc  all rights reserved news on davidalexandre c gros news home advertising board and executive moves energy health care hedge funds m  a private equity technology person davidalexandre c gros ▼ topic all topics ▼ organizations find news about organizations alumni find news on alumni of any org industries find news on a particular market your contacts find news on your contacts sign up for free daily alerts on this feed by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions follow change feed davidalexandre c gros neurocrine biosciences announces the appointment of julie cooke as chief people officer july    •  pr newswire  our chief people officer to lead our human resource function said davidalexandre c gros president and chief operating officer of neurocrine biosciences julies deep and  technical reports on biotech stocks  biogen alnylam pharma cascadian therapeutics and marinus pharma january    •  pr newswire  to 9 a share on january rd  alnylam announced that davidalexandre da gros md senior vice president and chief business officer plans to leave  neurocrine biosciences announces the appointment of davidalexandre gros md president and chief operating officer january    •  pr newswire  as president and chief operating officer � neurocrine is very pleased to welcome�dr gros�as our president and chief operating officer as we move forward with  alnylam announces management change and key promotion january    •  business wire   inc nasdaqalny the leading rnai therapeutics company today announced that davidalexandre da gros md senior vice president and chief business officer plans to leave  brexit  beyond uk told to wait pound pain infrastructure investment october    •  moneybeat  vote for brexit on june ” said the biopharma’s chief business officer davidalexandre gros crisis of globalization lies behind deutsche bank troubles it’s tempting to  pricing uproar shakes biotechsprofits on drugs could fall short october 9   •  the boston globe  private sources or alliances with pharma companies to fund their operations davidalexandre da gros senior vice president at alnylam one of the highestvalued precommercial biotechs  alnylam appoints senior vice president and chief business officer june    •  marketline newswire  alnylam pharmaceuticals inc a biotechnology company has appointed davidalexandre gros as senior vice president and chief business officer davidalexandre da gros  top former sanofi executive to join cambridge drugmaker alnylam june    •  boston business journal  ousted ceo chris viehbacher will be overseeing business development at alnylam pharmaceuticals davidalexandre gros  represents a highprofile addition to the management team of cambridgebased  related news feeds neurocrine biosciences inc biotechnology board and executive moves in biotechnology alumni of harvard university  harvard business school email linkedin facebook google tweet reddit permalink want to see the full history of news or view news on a particular date upgrade to relsci professional now start my free trial ➤ industry select a topic keyword go  ➤ find an organization select a topic keyword go  ➤ find a person select a topic keyword go  ➤ name of a school or name of an organization select a topic keyword go  ➤ thank you you are now subscribedplease wait for the page to refresh you are now subscribed to this feed you have unsubscribed to this feed thank you you can now subscribe to more relsci news feeds to subscribe to more than one feed please enter a password please confirm your password go  ➤ youve found a premium relsci pro feature follow news on your contacts upgrade to relsci pro now to easily sync your contacts and stay in the know on the news about the people important to you start my free trial ➤ still not convinced check out our full listing of features here not now youve found a premium relsci pro feature search news on keywords curate your news even further with the ability to filter feeds based on specific keywords mentioned in the articles start my free trial ➤ still not convinced check out our full listing of features here not now industries find news on a particular market people find news about people organizations find news about organizations alumni find news on alumni of any org your contacts find news on your contacts free daily alerts sign up for free daily alerts on this feed sign up ➤ by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions already have an account click here to login are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤